Guggenheim Capital LLC Genmab A/S Transaction History

Guggenheim Capital LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$35.27 - $42.24 $3,456 - $4,139	-98 Reduced 1.47%	6,563 $231,000
Q2 2023 Aug 11, 2023	SELL	$37.4 - $42.94 $3,814 - $4,379	-102 Reduced 1.51%	6,661 $253,000
Q1 2023 May 10, 2023	SELL	$34.88 - $43.22 $2,685 - $3,327	-77 Reduced 1.13%	6,763 $255,000
Q4 2022 Feb 14, 2023	SELL	$33.8 - $47.06 $1.31 Million - $1.83 Million	-38,799 Reduced 85.01%	6,840 $289,000
Q3 2022 Nov 14, 2022	SELL	$31.52 - $373.61 $74,387 - $881,719	-2,360 Reduced 4.92%	45,639 $1.47 Million
Q2 2022 Aug 15, 2022	BUY	$26.83 - $38.57 $88,324 - $126,972	3,292 Added 7.36%	47,999 $1.56 Million
Q1 2022 May 16, 2022	BUY	$30.95 - $39.68 $55,740 - $71,463	1,801 Added 4.2%	44,707 $1.62 Million
Q4 2021 Feb 14, 2022	SELL	$35.87 - $47.12 $5,344 - $7,020	-149 Reduced 0.35%	42,906 $1.7 Million
Q3 2021 Nov 15, 2021	SELL	$41.55 - $48.72 $42,796 - $50,181	-1,030 Reduced 2.34%	43,055 $1.88 Million
Q2 2021 Aug 13, 2021	BUY	$32.88 - $44.57 $88,052 - $119,358	2,678 Added 6.47%	44,085 $1.8 Million
Q1 2021 May 13, 2021	BUY	$30.92 - $44.4 $422,429 - $606,592	13,662 Added 49.24%	41,407 $1.36 Million
Q4 2020 Feb 16, 2021	BUY	$33.66 - $40.76 $933,896 - $1.13 Million	27,745 New	27,745 $1.13 Million

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Guggenheim Capital LLC with notifications on news.